Edesa Biotech Inc(EDSA-Q)NASDAQ
Today's Change
Real-Time Last Update
After Hours Change
After Hours Last Update
Volume
Latest News
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
ACCESSWIRE - Mon Nov 20, 2023
ACCESSWIRE
Mon Nov 20, 2023
TORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced favorable final results from a Phase 2b dose-ranging...
Edesa Biotech to Present at Dermatology Drug Development Summit
ACCESSWIRE - Thu Oct 26, 2023
ACCESSWIRE
Thu Oct 26, 2023
TORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, is...
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug
ACCESSWIRE - Wed Oct 25, 2023
ACCESSWIRE
Wed Oct 25, 2023
TORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Health Canada has approved the company's proposal...
Edesa Biotech Secures $10 Million Credit Facility with Company Founder
ACCESSWIRE - Thu Oct 12, 2023
ACCESSWIRE
Thu Oct 12, 2023
TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced it has entered into a...
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
ACCESSWIRE - Thu Oct 12, 2023
ACCESSWIRE
Thu Oct 12, 2023
TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23 million from the Government of...
Edesa Biotech Announces One-for-Seven Reverse Share Split
ACCESSWIRE - Tue Oct 10, 2023
ACCESSWIRE
Tue Oct 10, 2023
TORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa" or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today is announcing that it intends to...
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
ACCESSWIRE - Wed Aug 9, 2023
ACCESSWIRE
Wed Aug 9, 2023
TORONTO, ON / ACCESSWIRE / August 9, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended...
Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
ACCESSWIRE - Wed Jul 26, 2023
ACCESSWIRE
Wed Jul 26, 2023
TORONTO, ON / ACCESSWIRE / July 26, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will participate in a Fireside Chat and...
Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
ACCESSWIRE - Wed Jun 28, 2023
ACCESSWIRE
Wed Jun 28, 2023
TORONTO, ON / ACCESSWIRE / June 28, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced positive findings from an in vitro study of its monoclonal...
Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
ACCESSWIRE - Tue Jun 27, 2023
ACCESSWIRE
Tue Jun 27, 2023
TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed...
Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results
ACCESSWIRE - Thu May 11, 2023
ACCESSWIRE
Thu May 11, 2023
TORONTO, ON / ACCESSWIRE / May 11, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March...
Edesa Biotech to Participate in Swiss Biotech Day
ACCESSWIRE - Thu Apr 20, 2023
ACCESSWIRE
Thu Apr 20, 2023
TORONTO, ON / ACCESSWIRE / April 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will join a Canadian delegation of...
The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate
ACCESSWIRE - Tue Apr 4, 2023
ACCESSWIRE
Tue Apr 4, 2023
TORONTO, ON / ACCESSWIRE / April 4, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the World Health Organization (WHO) has adopted the...
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference
ACCESSWIRE - Thu Mar 23, 2023
ACCESSWIRE
Thu Mar 23, 2023
TORONTO, ON / ACCESSWIRE / March 23, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will participate in a Fireside Chat and...
Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
ACCESSWIRE - Thu Mar 16, 2023
ACCESSWIRE
Thu Mar 16, 2023
TORONTO, ON / ACCESSWIRE / March 16, 2023 / Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug candidate at a Late Breaking Abstract session of...
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
ACCESSWIRE - Wed Mar 15, 2023
ACCESSWIRE
Wed Mar 15, 2023
TORONTO, ON / ACCESSWIRE / March 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that the company and the U.S. Food and Drug...
Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
ACCESSWIRE - Fri Feb 10, 2023
ACCESSWIRE
Fri Feb 10, 2023
TORONTO, ON / ACCESSWIRE / February 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December...
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
ACCESSWIRE - Wed Feb 1, 2023
ACCESSWIRE
Wed Feb 1, 2023
TORONTO, ON / ACCESSWIRE / February 1, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has received approval from Health Canada for a...
Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
ACCESSWIRE - Tue Jan 17, 2023
ACCESSWIRE
Tue Jan 17, 2023
TORONTO, ON / ACCESSWIRE / January 17, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced preliminary, topline results from a Phase 2b clinical...
FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate
ACCESSWIRE - Tue Dec 20, 2022
ACCESSWIRE
Tue Dec 20, 2022
TORONTO, ON / ACCESSWIRE / December 20, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has received Fast Track designation from the U.S. Food and Drug...
Edesa Biotech Reports Fiscal Year 2022 Results
ACCESSWIRE - Fri Dec 16, 2022
ACCESSWIRE
Fri Dec 16, 2022
TORONTO, ON / ACCESSWIRE / December 16, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September...
Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference
ACCESSWIRE - Fri Dec 2, 2022
ACCESSWIRE
Fri Dec 2, 2022
TORONTO, ON / ACCESSWIRE / December 2, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, will...
Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market
ACCESSWIRE - Thu Nov 3, 2022
ACCESSWIRE
Thu Nov 3, 2022
TORONTO, ON / ACCESSWIRE / November 3, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing a private...
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
ACCESSWIRE - Fri Sep 30, 2022
ACCESSWIRE
Fri Sep 30, 2022
TORONTO, ON / ACCESSWIRE / September 30, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced final results from the Phase 2 portion of its ongoing...
Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference
ACCESSWIRE - Thu Sep 8, 2022
ACCESSWIRE
Thu Sep 8, 2022
TORONTO, ON / ACCESSWIRE / September 8, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will...